The agreement is said to be a six-figure deal, although the terms of the arrangement have not been released.
Swiss Medica cited recent studies which have shown that Mexico has a large consumer market in chronic pain, consisting of more than 10 million Mexicans, or about 10.6% of the population. The number of potential customers with significant purchasing power represents more than one million new customers in Mexico for the O24 pain neutralizer product.
Grant Johnson, president of Swiss Medica, outlined the steps he believes will make the pain relief a success: “First, the O24 pain neutralizer will soon be available across all of North America. Second, our products are of high quality that other major companies are prepared to invest significant financial resources in aligning with Swiss Medica to market our products in new markets. Third, we have launched our international expansion strategy with a widely respected company of an influential family in this country, and established the paradigm for future relationships in other countries.”